Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 16 Show results per page	View Search Criteria \| Help With Results

Last Modified: 1/1/2000 First Published: 8/1/1999


1.		Phase II Randomized Study of SCH 66336 vs Gemcitabine in Patients with Metastatic Adenocarcinoma of the Pancreas (Summary Last Modified 01/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				CWRU-SCH-1298 SPRI-C98-545-18, NCI-G99-1534

Last Modified: 4/20/2007 First Published: 10/1/1999


2.		Phase II Randomized Study of SCH 66336 Versus Gemcitabine in Patients With Metastatic Adenocarcinoma of the Pancreas (Summary Last Modified 01/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI, Pharmaceutical / Industry				MSKCC-98115 SPRI-C98-545-12, NCI-G99-1571

Last Modified: 4/20/2007 First Published: 11/1/1999


3.		Phase II Study of SCH 66336 in Patients With Metastatic Adenocarcinoma of the Pancreas Refractory to Gemcitabine (Summary Last Modified 03/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				UCLA-9906030 SPRI-P00346, NCI-G99-1610

Last Modified: 9/13/2005 First Published: 10/1/2000


4.		Phase II Study of SCH 66336 and Gemcitabine in Patients With Advanced Transitional Cell Carcinoma of the Urinary Tract

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Other				EORTC-16997 EORTC-GU-16997, EORTC-PAMM-16997, NCT00006351

Last Modified: 9/1/2001 First Published: 7/1/2001


5.		Phase II Randomized Study of Neoadjuvant SCH 66336 With or Without Gemcitabine Followed By Surgical Resection Versus Surgical Resection Alone in Patients With Resectable Primary Liver Cancer (Summary Last Modified 09/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				UCLA-0002038 NCI-G01-1958, NCT00020774


6.		Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530)(COMPLETED)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				P02530 NCT00073450

Last Modified: 7/20/2007 First Published: 11/22/2004


7.		Phase II Randomized Study of Anastrozole With or Without Lonafarnib in Postmenopausal Women With Hormone Receptor-Positive Stage IIIB, IIIC or IV Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				Postmenopausal				NCI, Pharmaceutical / Industry				UCLA-0403073-01 SPRI-P03480, NCT00098904


8.		Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-Line Treatment of Ovarian Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Other				AGO-OVAR 15 NCT00281515

Last Modified: 4/1/2000 First Published: 8/1/1999


9.		Phase I Study of SCH 66336 with Fluorouracil and Leucovorin Calcium in Patients with Advanced Cancer (Summary Last Modified 04/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				MSKCC-99020 SPRI-C98-564-01, NCI-G99-1540, NCT00003956

Last Modified: 4/1/2000 First Published: 9/1/1999


10.		Phase I Study of Oral SCH 66336 in Patients with Solid Tumors (Summary Last Modified 04/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 and over				Pharmaceutical / Industry				EORTC-16979 SPRI-I97-211

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute